Mirtazapin

Из Википедије, слободне енциклопедије
Mirtazapin
Mirtazapin.svg
Mirtazapine-from-xtal-2003-US-patent-6723845-3D-balls.png
IUPAC ime
(±)-2-metil-1,2,3,4,10,14b-heksahidropirazino[2,1-a]pirido[2,3-c][2]benzazepin
Klinički podaci
Prodajno ime Remeron, Avanza, Zispin
Drugs.com Monografija
MedlinePlus a697009
Kategorija trudnoće
  • C
Način primene Oralno
Pravni status
Pravni status
  • Rx-only
Farmakokinetički podaci
Bioraspoloživost 50%[1]
Vezivanje proteina 85%[1]
Metabolizam Hepatički (CYP1A2, CYP2D6, i CYP3A4)[2][1]
Poluvreme eliminacije 20–40 sata[1]
Izlučivanje Urin (75%)[1]
Izmet (15%)[1]
Identifikatori
CAS broj 61337-67-5 ДаY
ATC kod N06AX11 (WHO)
PubChem CID 4205
DrugBank DB00370 ДаY
ChemSpider 4060 ДаY
UNII A051Q2099Q ДаY
KEGG D00563 ДаY
ChEBI CHEBI:6950 ДаY
ChEMBL CHEMBL654 ДаY
Sinonimi 6-Azamianserin, Org 3770
Hemijski podaci
Formula C17H19N3
Molarna masa 265,35 g/mol
Fizički podaci
Gustina 1,22 g/cm3
Tačka topljenja 114 to 116 °C (237 to 241 °F)
Tačka ključanja 432 °C (810 °F)
Solubility in water Rastvoran u metanolu i hloroformu mg/mL (20 °C)
  (verify)

Mirtazapin (Remeron, Avanza, Zispin) je noradrenergički i specifični serotonergički antidepresiv (NaSSA) koji je razvila kompanija Organon International u Sjedinjenim Državama 1990. godine. On se prvenstveno koristi za lečenje depresije. On isto takao nalazi primenu kao anksiolitik, hipnotik, antiemetik i stimulant apetita. On je strukturno sličan sa mianserinom, i klasifikuje se kao tetraciklični antidepresant (TeCA).

Medicinska upotreba[уреди]

Mirtazapin se prvenstveno koristi za tretiranje kliničke depresije i drugih poremećaja raspoloženja.[3][4]

On isto tako može da bude koristan u tretiranju sledećih oboljenja, mada nije odobren za te primene:

Reference[уреди]

  1. 1,0 1,1 1,2 1,3 1,4 1,5 Timmer CJ, Sitsen JM, Delbressine LP (2000). „Clinical pharmacokinetics of mirtazapine”. Clinical Pharmacokinetics. 38 (6): 461—74. doi:10.2165/00003088-200038060-00001. PMID 10885584. 
  2. 2,0 2,1 Anttila SA, Leinonen EV (2001). „A review of the pharmacological and clinical profile of mirtazapine”. CNS Drug Reviews. 7 (3): 249—64. doi:10.1111/j.1527-3458.2001.tb00198.x. PMID 11607047. 
  3. Gorman JM (1999). „Mirtazapine: clinical overview”. J Clin Psychiatry. 60 Suppl 17: 9—13; discussion 46—8. PMID 10446735. 
  4. Benjamin S, Doraiswamy PM (2011). „Review of the use of mirtazapine in the treatment of depression”. Expert Opinion on Pharmacotherapy. 12 (10): 1623—32. doi:10.1517/14656566.2011.585459. PMID 21644844. 
  5. Goodnick PJ, Puig A, DeVane CL, Freund BV (1999). „Mirtazapine in major depression with comorbid generalized anxiety disorder”. J Clin Psychiatry. 60 (7): 446—8. doi:10.4088/JCP.v60n0705. PMID 10453798. 
  6. 6,0 6,1 6,2 6,3 Croom KF, Perry CM, Plosker GL (2009). „Mirtazapine: a review of its use in major depression and other psychiatric disorders”. CNS Drugs. 23 (5): 427—52. doi:10.2165/00023210-200923050-00006. PMID 19453203. 
  7. Muehlbacher M, Nickel MK, Nickel C; et al. (2005). „Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study”. Journal of Clinical Psychopharmacology. 25 (6): 580—3. doi:10.1097/01.jcp.0000186871.04984.8d. PMID 16282842. 
  8. Koran LM, Quirk T, Lorberbaum JP, Elliott M (2001). „Mirtazapine treatment of obsessive-compulsive disorder”. J Clin Psychopharmacol. 21 (5): 537—9. doi:10.1097/00004714-200110000-00016. PMID 11593084. 
  9. Carpenter LL, Leon Z, Yasmin S, Price LH (1999). „Clinical experience with mirtazapine in the treatment of panic disorder”. Ann Clin Psychiatry. 11 (2): 81—6. doi:10.3109/10401239909147053. PMID 10440525. 
  10. Carli V, Sarchiapone M, Camardese G, Romano L, DeRisio S (2002). „Mirtazapine in the treatment of panic disorder”. Arch. Gen. Psychiatry. 59 (7): 661—2. doi:10.1001/archpsyc.59.7.661. PMID 12090820. 
  11. Hrdlicka M, Beranova I, Zamecnikova R, Urbanek T (2008). „Mirtazapine in the treatment of adolescent anorexia nervosa. Case-control study”. European Child & Adolescent Psychiatry. 17 (3): 187—9. doi:10.1007/s00787-007-0670-8. PMID 18357426. 
  12. Hartmann PM (1999). „Mirtazapine: a newer antidepressant”. Am Fam Physician. 59 (1): 159—61. PMID 9917581. 
  13. Jindal RD (2009). „Insomnia in patients with depression: some pathophysiological and treatment considerations”. CNS Drugs. 23 (4): 309—29. PMID 19374460. 
  14. Nutt DJ (2002). „Tolerability and safety aspects of mirtazapine”. Human Psychopharmacology. 17 Suppl 1: S37—41. doi:10.1002/hup.388. PMID 12404669. 
  15. 15,0 15,1 Li TC, Shiah IS, Sun CJ, Tzang RF, Huang KC, Lee WK (2011). „Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature”. The Journal of ECT. 27 (2): 165—7. doi:10.1097/YCT.0b013e3181e63346. PMID 21602639. 
  16. Kast RE, Foley KF (2007). „Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects”. Eur J Cancer Care (Engl). 16 (4): 351—4. doi:10.1111/j.1365-2354.2006.00760.x. PMID 17587360. 
  17. Landowski J (2002). „[Mirtazapine--an antidepressant]”. Psychiatria Polska (на језику: Polish). 36 (6 Suppl): 125—30. PMID 12647431. 
  18. Chinuck RS, Fortnum H, Baldwin DR (2007). „Appetite stimulants in cystic fibrosis: a systematic review”. Journal of Human Nutrition and Dietetics : the Official Journal of the British Dietetic Association. 20 (6): 526—37. doi:10.1111/j.1365-277X.2007.00824.x. PMID 18001374. 
  19. Davis MP, Khawam E, Pozuelo L, Lagman R (2002). „Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project”. Expert Review of Anticancer Therapy. 2 (4): 365—76. doi:10.1586/14737140.2.4.365. PMID 12647979. 
  20. Twycross R, Greaves MW, Handwerker H; et al. (2003). „Itch: scratching more than the surface”. QJM : Monthly Journal of the Association of Physicians. 96 (1): 7—26. doi:10.1093/qjmed/hcg002. PMID 12509645. 
  21. Greaves MW (2005). „Itch in systemic disease: therapeutic options”. Dermatologic Therapy. 18 (4): 323—7. doi:10.1111/j.1529-8019.2005.00036.x. PMID 16297004. 
  22. Colombo B, Annovazzi PO, Comi G (2004). „Therapy of primary headaches: the role of antidepressants”. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 25 Suppl 3: S171—5. doi:10.1007/s10072-004-0280-x. PMID 15549531. 
  23. Tajti J, Almási J (2006). „[Effects of mirtazapine in patients with chronic tension-type headache. Literature review]”. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakológiai Egyesület Lapja = Official Journal of the Hungarian Association of Psychopharmacology (на језику: Hungarian). 8 (2): 67—72. PMID 17073214. 

Literatura[уреди]

  • Stimmel GL, Dopheide JA, Stahl SM (1997). „Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects”. Pharmacotherapy. 17 (1): 10—21. PMID 9017762. 
  • Anttila SA, Leinonen EV (2001). „A review of the pharmacological and clinical profile of mirtazapine”. CNS Drug Rev. 7 (3): 249—64. doi:10.1111/j.1527-3458.2001.tb00198.x. PMID 11607047. 

Spoljašnje veze[уреди]